PGR and neoplasm: With regard to the BCSS status, MRM, larger tumor size, lymph node involvement, lobular subtype, mixed ductal and lobular subtype, high histological grade, hormone therapy other than tamoxifen, and chemotherapy were significantly associated with an increased risk of BC-specific mortality in the univariate analysis (Table 3); alternatively, PgR (HR, 0.484; 95% CI, 0.263–0·888; p = 0.019) expression significantly reduced the risk.